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private sector respectively in Germany and on the Medicare physician fee schedule
in USA. In USA is very difficult to analyze physician’s cost of production. In Spain
regional outpatient tariffs are used as resource components without inclusion of
health staff cost.CONCLUSIONS:Cost data availability is limited and varies widely.
An improvement approach might be the creation of national database used as
reference for cost assessment.
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OBJECTIVES: During the last decade, with the arrival of new innovative vaccines,
there was a huge increase in the number of papers on economic evaluation of
vaccination programmes. Our study had a 3-fold objective: 1) Appraise available
methodological papers dealing with specificities of vaccines in term of health eco-
nomics; 2) Illustrate the impact of each issue in term of decision-making process
with concrete examples; and 3) Identify futures challenges. METHODS: A compre-
hensive literature search was conducted to identify methodological papers dealing
with specificities of economic evaluations of vaccines. Each issue was illustrated
with concrete examples of cost-effectiveness analyses recently performed for HPV
vaccines, or pneumococcal diseases. RESULTS: Except guidelines issued in 2008 by
the WHO and a few general papers, most of methodological papers focused on
modelling techniques and showed a trend in using more and more sophisticated
methods (e.g. calibration). Several papers highlighted the need for having strong
dynamic transmission models of infectious diseases to evaluate appropriately the
cost-effectiveness of vaccination programmes. Other papers focused on the issue
of discounting, and showed the extreme impact of discounting for some vaccines
given this long-term assessment, possibly warranting an alternative method of
discounting for vaccines. Fewer papers highlighted the different type of clinical
evidence compared with curative pharmaceutical drugs, in particular the need to
model immunological responses into clinical endpoints of disease and short-term
efficacy into long-term effectiveness. Although there is an increasing level of ex-
pertise in the field, other important issues such as the choice of realistic assump-
tions (coverage rates or vaccine prices) and the inclusion of externalities (i.e.
changes in the epidemiology of the infection) are not well analysed.
CONCLUSIONS: It is important for decision makers to keep in mind the above
vaccine specificities when they assess the cost-effectiveness of new vaccination
programmes in order to provide relevant conclusions.
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Increase in accessibility and affordability of health care services have been consid-
ered as important policy objectives since the beginning 1980s in Iran. However,
current 60- 70% out-of-pocket payments creates a barrier to an equal access to
quality health services especially in terms of new medicines. This affects equity
issues and consequently the “health” in Iran. Currently, the quasi-government
health insurance organizations considered as main budget holders or purchasers
of medicines and health care services, do not consider comprehensive economic
evaluations (Cost-effectiveness plus Budget impact analyses) for their reimburse-
ment decisions. The present study is introducing a standard Budget Impact Anal-
yses (BIAs) model for the first time in Iran. The main purpose is providing the health
care budget decision makers with a practical tool improving resource allocation as
well as accelerating and facilitating the process of pharmaceutical reimbursement
decision making to address the problem of considerable out-of-pocket payments in
Iran. In the current study, A literature systematic review was conducted on the
international database pubmed to find: 1) Standard guidelines published for BIAs
and 2) Empirical studies doing Pharmaceutical BIAs, published in English language
since Jan 2000 to Dec 2011. Four international standard guidelines and 22 empirical
studies on BIAs were reviewed to provide a comprehensive standard model for
conducting BIAs. They also include practical examples for theoretical recommen-
dations. Moreover, semi-structured interviews were also conducted to ask policy
makers opinions about the necessity of doing BIAs in Iran‘s health care financing
system as well as their opinions about the different parts of the proposed model.
The final model consists of general and detailed recommendations which were
extracted mainly from ISPOR task force report on Principles of Good Practice for
BIAs and other reviewed guidelines. There also were recommendations made by
Iranian policy makers which make the model much more practical for conducting
standard BIAs in Iran.
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OBJECTIVES: Many individuals with long-term care needs rely on informal care to
support them in their daily living. Although public authorities tend to see informal
care as free, caring imposes significant costs on caregivers. However, measuring
and valuing informal care remains a challenge partly due to the absence of clear
guidelines on the topic and partly due to the lack of consensus among economists
on the best methods to use. This review describes the methods used to measure
and monetarily value informal care and discusses their advantages and
limitations. METHODS: Review of: 1) the methods available to measure time; 2)
methods available to value informal care time; and 3) application in published
economic evaluations. RESULTS: Only the diary and the recall methods have been
used in cost-effectiveness analysis, although direct observation and experience
sampling may provide more accurate estimates of time use. The traditional meth-
ods to value time are the opportunity cost, proxy good and contingent valuation
methods. Recently, the well-being method and applications of conjoint analysis to
informal care have been developed. The value of informal care varies widely de-
pending on the methods used. CONCLUSIONS: Informal care should not be viewed
as costless or free since the time inputs into informal care generate costs borne by
the caregiver and society as a whole. Failure to consider informal care may affect
reimbursement decisions and shift costs to patients and their families. The mon-
etary value of informal care can be estimated using existing methods. The clear
advantage of using monetary methods is that results can potentially be included in
cost side of any type of economic evaluations. However, different methods give
different answers both in terms of time-use data and value of informal care. Clear
guidelines are needed on the preferred methods to measure and value informal
care time.
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OBJECTIVES: To assess the validity of cost calculation from incomplete data col-
lection and point out its consequence on bias and on precision of study results.
METHODS:Over a one-year period resource use data from 234 elderly patients with
myocardial infarction were collected quarterly. Applying unit costs, costs for each
quarter were estimated. To examine different strategies of incomplete data collec-
tion, two different methods (inter-/extrapolation) with three different time frames
(omitting quarter two and/or three) were applied and compared with complete
data collection. Sample size was recalculated in response to the variation of cost
estimates due to incomplete data collection. RESULTS: Sum of cost estimation
from complete and incomplete data collection in the case of omitting information
of quarter two or three showed no significant difference. When the time sampling
included only 50% of the full information (omitting quarter two and three) costs
were significantly lower by 3.9% (extrapolation) and 4.6% (interpolation). Generally,
an increase in the standard deviation by 1% leads to an increase in sample size by
2% in the case of a single outcome. Thus, based on observed increased standard
deviation due to incomplete cost collection a larger sample size by about 3% would
be required. This would be efficient, since more time is saved due to incomplete
data collection than extra time is required for additional patients. CONCLUSIONS:
In economic evaluation, cost data can be collected efficiently by reducing fre-
quency of data collection. This can be achieved by data collection for shorter peri-
ods (incomplete data collection) or extending recall windows (complete data col-
lection). When applying the method of incomplete data collection, sample size
calculation has to be modified due to increased standard deviation. This approach
is suitable to enable economic evaluation with lower costs to both study partici-
pants and investigators.
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OBJECTIVES: The Institute for Quality and Efficiency in Health Care (IQWiG) devel-
oped—in a consultation process with an international expert panel—the efficiency
frontier (EF) approach to satisfy the legal requirements for economic evaluation in
Germany’s statutory health insurance system. Here we evaluate established tools
for assessing and communicating uncertainty in terms of their applicability to the
EF approach and, where necessary, suggest adjustments to them.METHODS: Tools
to dasplay uncertainty were applied to the EF approach with a simulated data set.
The tools are (i) displays of overall uncertainty (scatter plots, confidence bands,
contour plots); (ii) displays of uncertainty around the reimbursable price (confi-
dence intervals, a modified cost effectiveness acceptability curve, the net health/
monetary benefit approach), and (iii) the ANCOVA approach. RESULTS: We found
that, within the EF approach, the substantial implications of most tools was not
always easy to interpret. Hence, we propose the use of price reimbursement ac-
ceptability curves or the net health benefit approach. CONCLUSIONS: This closes a
gap for handling uncertainty in the economic evaluation approach of the IQWiG
methods. However, the role of statistical testing in determining reimbursable
prices is yet to be defined.
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OBJECTIVES: Consideration of the value presented to the health service by a new
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